France· FR:66316458
OXLUMO 94,5 mg/0,5mL, solution injectable
A lumasiran product containing lumasiran sodique, registered in France by ALNYLAM NETHERLANDS (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LUMASIRAN SODIQUE
- Manufacturer
- ALNYLAM NETHERLANDS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302174431 flacon(s) en verre de 0,5 mlEUR 46.93
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsOxlumo 189 mg/ml, oplossing voor injectieAlnylam Netherlands B.V.
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- SwitzerlandOxlumo 94.5 mg / 0.5 ml, InjektionslösungAlnylam Switzerland GmbH
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- United KingdomOxlumo 94.5mg/0.5ml solution for injection vialsAlnylam UK Ltd
- IcelandOxlumoAlnylam Netherlands B.V.
- PolandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxlumo
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc0b2fa1-a731-4f43-960e-7ca03fa7218b GET /v1/drugs/dc0b2fa1-a731-4f43-960e-7ca03fa7218b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66316458",
"date_amm": "2020-11-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1496",
"substance": "LUMASIRAN SODIQUE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.